免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

Simplexa 先天性巨细胞病毒直接检测和Simplexa 先天性巨细胞病毒阳性对照包

K号: K202755 · 2022-11-05

决定日期2022-11-05
产品代码QDZ
咨询委员会抱歉,您提供的内容“MI”不足以进行翻译。请提供完整的医疗设备监管文本,以便我能够进行准确的翻译。
决定实质等同

器械摘要

Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack is the device name listed in this FDA 510(k) record. The listed applicant is Diasorin Molecular, LLC. It received FDA 510(k) clearance on 2022-11-05 under 510(k) number K202755. The device is classified under product code QDZ. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack?

Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack is a medical device that received FDA 510(k) clearance on 2022-11-05. The listed applicant is Diasorin Molecular, LLC. The 510(k) number is K202755.

When did Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack receive FDA 510(k) clearance?

Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack received FDA 510(k) clearance on 2022-11-05, under 510(k) number K202755.

Who is the listed applicant for Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack?

The FDA 510(k) record lists Diasorin Molecular, LLC as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack?

The FDA product code for Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack is QDZ.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

列明Diasorin Molecular, LLC为申报人的其他记录

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

查看所有 13 个设备 →

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息,请务必参考官方记录。

↑